Search Results
May 05, 2026, 07:00 ET Samsung Biologics Listed on Dow Jones Best-in-Class World Index for Fifth Consecutive Year
cutting-edge technologies and expertise to advance diverse modalities, including multispecific antibodies, fusion proteins, antibody-drug conjugates, and mRNA therapeutics. By implementing its ExellenS™ framework across its manufacturing network with standardized designs, unified processes, and advanced digitalization,
More news about: Samsung Biologics
May 04, 2026, 10:30 ET Biologics Safety Testing Market worth $9.66 billion by 2031 | MarketsandMarkets™
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=34624144The growth of advanced modalities such as cell & gene therapies and mRNA products is a major driver of the biologics safety testing market. Additionally, the expanding pipeline of biologics and biosimilars, along with stringent
More news about: MarketsandMarkets
May 01, 2026, 21:00 ET The 28th China Beijing International High-Tech Expo Grand Opening Soon
matchmaking. Multinational corporations such as AstraZeneca and Sanofi will showcase state-of-the-art technologies covering tumor immunotherapy and mRNA vaccines. Innovative enterprises including Seaway and iFLYTEK Spark will also attend the event to jointly facilitate global exchanges and cooperation
More news about: CCTV.com
May 01, 2026, 21:00 ET The 28th China Beijing International High-Tech Expo Grand Opening Soon
matchmaking. Multinational corporations such as AstraZeneca and Sanofi will showcase state-of-the-art technologies covering tumor immunotherapy and mRNA vaccines. Innovative enterprises including Seaway and iFLYTEK Spark will also attend the event to jointly facilitate global exchanges and cooperation
More news about: CCTV.com
May 01, 2026, 18:12 ET Rockefeller Foundation Celebrates 60th Anniversary of Nairobi Office and 100 Years of Impact in Africa
stability. From an 11-country West African surveillance network to heat-health innovation in Senegal to the development of Africa's first AI-designed mRNA vaccine for Rift Valley Fever, these programs demonstrate how catalytic investments can enable the necessary shift toward locally led innovations grounded
More news about: The Rockefeller Foundation
May 01, 2026, 09:00 ET Diakonos Oncology Reports Positive Clinical Data from Phase 1 Pancreatic Cancer Study and Expanded Access Program in Glioblastoma at AACR and AAN 2026
patient-derived double-loaded dendritic cell therapy that combines tumor lysate and amplified tumor-derived mRNA. The immunotherapy is made with a patient's dendritic cells combined with mRNA and proteins prepared from freshly obtained patient tumor specimens.The unique double-loading approach,
More news about: Diakonos Oncology
Apr 30, 2026, 14:00 ET Cincinnati Children's Releases 2025 Research Annual Report Highlighting Discoveries Poised to Improve Health Across the Life Span
AntibioticsMaking Emotional Health Part of Everyday Pediatric CareReimagining Allergy Treatment With mRNA Technology
More news about: Cincinnati Children's Hospital Medical Center
Apr 29, 2026, 10:00 ET Penn Medicine and CHOP Name Founding Director for Lurie Autism Institute, Advancing New Era of Autism Research
Penn Medicine teams have pioneered discoveries that have shaped modern medicine, including CAR T cell therapy for cancer and the Nobel Prize-winning mRNA technology used in COVID-19 vaccines.The University of Pennsylvania Health System cares for patients in facilities and their homes stretching
More news about: Children's Hospital of Philadelphia
Apr 28, 2026, 16:05 ET PTC Therapeutics Reports Positive Topline Results from Month 24 Interim Analysis of PIVOT-HD Extension Study of Votoplam
acts via a unique mechanism to promote the inclusion of a novel pseudoexon containing a premature termination codon, thus triggering Huntingtin (HTT) mRNA degradation and subsequent reduction in HTT protein levels. Votoplam was discovered from PTC's validated splicing platform, following the successful
More news about: PTC Therapeutics, Inc.
Apr 28, 2026, 09:28 ET PTC Therapeutics to Report Results from PIVOT-HD Long Term Extension Study
acts via a unique mechanism to promote the inclusion of a novel pseudoexon containing a premature termination codon, thus triggering Huntingtin (HTT) mRNA degradation and subsequent reduction in HTT protein levels. Votoplam was discovered from PTC's validated splicing platform, following the successful
More news about: PTC Therapeutics, Inc.
Apr 28, 2026, 07:57 ET U.S. FDA Grants Breakthrough Device Designation to Laguna Diagnostics' mRNA Gene Biomarker Test to Aid in Differentiation of Schizophrenia and Bipolar I Disorder
Diagnostics, LLC is focused on developing rapid, objective, blood-based mRNA biomarker tests to improve the diagnosis and differentiation of psychiatric disorders. This breakthrough in vitro diagnostic represents a novel blood-based mRNA biomarker approach supported by a clearly articulated biological rationale
More news about: Laguna Diagnostics, LLC
Apr 28, 2026, 07:00 ET Ascidian to Highlight Progress of Lead Program in Stargardt and Platform Advancements Across Therapeutic Areas at ASGCT 2026 Annual Meeting
Convention & Exhibit CenterSession: Poster ReceptionPresentation ID: 2471Poster Presentation: MSH3 Pre-mRNA Splice Modulation in the Treatment of Repeat Expansion DisordersDate: Wednesday, May 13Time: 5:00 - 6:30 PMLocation:
More news about: Ascidian Therapeutics
Apr 28, 2026, 04:07 ET Ivonescimab Receives Major Recommendations Across Multiple Therapies in the 2026 CSCO NSCLC Guideline
platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms. Supported by a global-standard GMP manufacturing infrastructure and a highly efficient,
More news about: Akeso, Inc.
Apr 24, 2026, 02:58 ET CMUH and Partners Unveil Breakthrough Targeted Exosome Platform for Non-Invasive Spinal Cord Injury Repair
International Biotechnology Co., Ltd. and SHINE OUT BIO TECHNOLOGY CO., LTD., the platform facilitates intravenous, lesion-targeted delivery of BDNF mRNA and improved motor coordination in preclinical models.TAICHUNG, April 24,
More news about: China Medical University Hospital
Apr 23, 2026, 08:02 ET CREATE Medicines Doses First Patient in Phase 1/2 Study of MT-304, a First-in-Class Multi-immune In Vivo CAR Therapy Targeting HER2-Positive Solid Tumors
therapies," said Matthew Maurer, M.D., Chief Medical Officer of CREATE. "Dosing the first patient with MT-304 reflects our ability to rapidly iterate on our mRNA-LNP platform to meet the clinical urgency. We are now engaging multiple arms of immunity simultaneously, an approach we believe can unlock durable responses
More news about: CREATE Medicines, Inc.
Apr 22, 2026, 02:50 ET Samsung Biologics Reports First Quarter 2026 Financial Results
cutting-edge technologies and expertise to advance diverse modalities, including multispecific antibodies, fusion proteins, antibody-drug conjugates, and mRNA therapeutics. By implementing its ExellenS™ framework across its manufacturing network with standardized designs, unified processes, and advanced digitalization,
More news about: Samsung Biologics
Apr 21, 2026, 22:10 ET Ractigen Therapeutics Presents Positive Phase I Data for RAG-17 in SOD1-ALS at the 2026 AAN Annual Meeting, Demonstrating 81% Reduction in Neurofilament Light Chain
designed using Ractigen's proprietary SCAD™ delivery platform technology to specifically target and silence the superoxide dismutase 1 (SOD1) gene mRNA. Mutations in the SOD1 gene cause a toxic gain-of-function and are a known cause of familial ALS. By reducing the production of the toxic mutant SOD1
More news about: Ractigen Therapeutics
Apr 21, 2026, 08:30 ET HKeybio Launches World's First NHP Hidradenitis Suppurativa Model with High Clinical Consistency to Tackle Global Drug R&D Bottleneck
subjects, a signature feature of human HS that drives neutrophil transepithelial migration and chronic inflammation.Molecular Alignment: mRNA expression profiling shows significant upregulation of key HS-related genes, such as IL-1A: 15.3-fold increase, IL-17B: 12.7-fold increase, TNF:
More news about: HKeyBio
Apr 21, 2026, 06:30 ET Flagship Pioneering Launches Serif Biomedicines to Establish Modified DNA as a New Biotechnology
Following Flagship's origination of generative protein and mRNA platforms, Serif is pioneering Modified DNA medicines to program the foundational information layer of biologySerif to present data at an upcoming scientific meeting demonstrating tolerability
More news about: Flagship Pioneering
Apr 20, 2026, 22:54 ET Cadonilimab Combination Demonstrates Promising Survival Benefit in Locally Advanced Pancreatic Cancer: Phase II COMPASSION-26 Data Presented at AACR 2026
platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms. Supported by a global-standard GMP manufacturing infrastructure and a highly efficient,
More news about: Akeso, Inc.
Apr 20, 2026, 10:00 ET AACR 2026 Oral Presentation: Abogen Presents Preliminary Results of ABO2203 (mRNA-Encoded CD3×CD19 TCE) from First-in-Human Clinical Study in R/R B-NHL
University School of Medicine. ABO2203 is a lipid nanoparticle (LNP)-formulated mRNA drug candidate encoding a CD3×CD19 bispecific T-cell engager (TCE). By enabling in vivo TCE expression via mRNA, ABO2203 is designed to mitigate cytokine release syndrome (CRS) while maintaining
More news about: Abogen
Apr 20, 2026, 10:00 ET AACR 2026 Oral Presentation: Abogen Presents Preliminary Results of ABO2203 (mRNA-Encoded CD3×CD19 TCE) from First-in-Human Clinical Study in R/R B-NHL
University School of Medicine. ABO2203 is a lipid nanoparticle (LNP)-formulated mRNA drug candidate encoding a CD3×CD19 bispecific T-cell engager (TCE). By enabling in vivo TCE expression via mRNA, ABO2203 is designed to mitigate cytokine release syndrome (CRS) while maintaining
More news about: Abogen
Apr 20, 2026, 09:00 ET Eclipsebio Launches eCOMPASS™, an AI-Enabled Lab-in-the-Loop Platform for RNA Therapeutic Development
in-house prototyping at R&D scale, and deep sequencing-based characterization (eMERGE™) into a single iterative workflow.In a Cas9 mRNA case study, eCOMPASS-designed candidates achieved a 400% increase in protein expression and a 58% increase in editing efficiency over baseline.With
More news about: Eclipsebio
Apr 20, 2026, 08:00 ET Argo Biopharma Doses First Patients in Phase II Clinical Trials of siRNA Therapy BW-40202
meaningful difference for patients," said Dr. Dongxu Shu, co-founder and CEO of Argo Biopharma.BW-40202 is an siRNA therapeutic that targets CFB mRNA in the liver. It utilizes an RNA interference (RNAi) mechanism to suppress CFB expression, thereby reducing serum CFB protein levels and inhibiting
More news about: Argo Biopharmaceutical Co., Ltd
Apr 18, 2026, 19:01 ET Penn Medicine, Children's Hospital of Philadelphia team awarded Breakthrough Prize for developing gene therapy for inherited blindness
Penn Medicine teams have pioneered discoveries that have shaped modern medicine, including CAR T cell therapy for cancer and the Nobel Prize-winning mRNA technology used in COVID-19 vaccines.The University of Pennsylvania Health System cares for patients in facilities and their homes stretching
More news about: Children's Hospital of Philadelphia